2. 15+ 35 $86.7M 44 869 654 111 23 Corporate Strategy & Outreach
partner meetings with corporations
Programs & Resources 35
programs hosted
Pennovation Center
PCI supports and encourages technology innovation at the Pennovation Center
Positive Momentum 44
Press mentions
R&D Alliances
$86.7M
awarded for 15 Alliance Agreements
Patents
869
patents filed
111
U.S. patents issued
Agreements
654
commercial agreements executed
Startup Companies 23
PCI-facilitated Penn spin outs

4. PCI Technologies www.pci.upenn.edu/bio2018
Method to Determine Risk of Preterm Birth
Bioengineered Brain Pathways to Reconstruct the Connectome
Inventor: Michal Elovitz, MD
Inventor: D. Kacy Cullen, PhD
A large study of pregnant women confirmed the association of specific cervicovaginal bacteria with preterm birth risk. These results indicate that identification of bacteria could be used as a method for determining a patient’s risk of preterm birth.
The first “tissue engineered nigrostriatal pathway” fully constructed outside the body emulates the form and function of the natural long-distance pathway in the brain. The new pathway is microinjected to physically replace the missing pathway, re-connecting distinct brain regions, effectively “reversing the clock” on Parkinson’s Disease.

5. Early Detection of Pancreatic Cancer
PCI Technologies
Early Detection of Pancreatic Cancer
Novel class of therapeutics for treatment of lupus and other autoimmune and inflammatory conditions
Inventor: Kenneth S. Zaret, PhD
Inventor: Roger A. Greenberg, MD, PhD
In an effort to develop early diagnostic prognostic of pancreatic ductal adenocarcinoma (PDAC), Dr. Zaret has developed a 2-protein panel for early detection of pancreatic ductal adenocarcinoma with a specificity of 98%, the combination of THBS2 and CA19-9 yielding a sensitivity of 87% for PDAC.
First in class compounds inhibiting BRISC (BRCC36 isopeptidase complex) deubiquitinating enzymes for treatment of autoimmune diseases, including several potent and specific lead BRISC inhibitors optimized using medicinal chemistry and rational drug design approaches.

6. PCI Technologies www.pci.upenn.edu/bio2018
Noninvasive Diagnostic for Early Prognosis and Diagnosis of Organ Rejection
Monoclonal Antibodies for treatment of Parkinson’s Disease and related neurodegenerative disorders
Inventor: Prashanth Vallabhajosyula, MD
Inventors: Kelvin Luk, Kurt Brunden, Virginia Lee, John Trojanowski,
and Dustin Covell
Method for early prediction of acute and chronic rejection of a transplanted organ by analyzing exosomes specific to transplanted organ in recipient’s biological fluids.
Penn scientists have generated a new series of monoclonal antibodies that recognize a misfolded protein implicated in Parkinson’s disease and related neurodegenerative disorders.

7. PCI Technologies www.pci.upenn.edu/bio2018
Novel therapeutics for treatment of Alzheimer’s Disease and other neurodegenerative conditions
Inventors: Kurt Brunden, Virginia Lee, John Trojanowski and Carlo Ballatore
The University of Pennsylvania has recently received a US Patent #9,649,317 claiming the use of certain small molecules that upon oral administration cross the blood-brain barrier and enhance microtubule stabilization in the brains of mice.
Based on prior work from Penn scientists and others, this microtubule-stabilizing activity in the brain strongly suggests that the compounds may have utility in Alzheimer’s disease and other neurodegenerative conditions, where there is evidence that altered microtubule integrity and faulty axonal transport contribute to the neuron loss of these diseases.
BOB techs

8. Penn Startups Pinpoint Therapeutics
A Differentiated Approach to Adoptive Cellular Therapy
Targeting the Lysosome: A New Approach to Cancer Therapy
A unified approach to targeting the lysosome’s degradative and growth signaling roles to develop novel therapeutics
Pioneering the Development of
CAR-Macrophages

9. Penn Startups Quantitative Radiology Solutions
Gold Nanoparticles for Treatment of Cancer
Automatic Anatomy Recognition© (AAR)
Pre-clinical stage biotechnology startup founded by Penn faculty to develop and commercialize biodegradable gold nanoparticles (BGNP) for treating cancer
Helping physicians make optimal treatment decisions by analyzing medical images

10. 4th 6th 654 $100M PCI Bragging Points Ranked 4th
World’s Most Innovative Universities
Reuters (2017)
6th
Ranked 6th:
top 25 university tech transfer and commercialization index
The Milken Institute (2017)
654
agreements
Facilitated the highest number of agreements in Penn history (FY2017)
$100M
Facilitated over $100M of licensing income
and sponsored research funding at Penn (FY2016)